Combination therapy in osteoporosis: Basic therapy plus specific osteoporosis drug;Kombinationstherapie bei osteoporose: Basistherapie plus spezifisches Osteoporosemedikament

Medizinische Monatsschrift fur Pharmazeuten

Volumn 32, Issue 4, 2009, Pages 137-140

  Ringe, Johann D ^a,b  

^a Leverkusen ^*  (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; VITAMIN D;

CALCIUM ABSORPTION; HUMAN; OSTEOPOROSIS; REVIEW; RISK FACTOR;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CALCIUM; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; HUMANS; OSTEOPOROSIS; VITAMIN D; VITAMINS;

EID: 65249105499     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Ringe JD. Osteoporose Dialog: 100 Fragen - 100 Antworten. 2. überarbeitete Auflage. Stuttgart, New York: Georg Thieme Verlag, 2003.
2. Ringe JD. Pathophysiology of osteoporosis. In: Rizzoli R (ed.). Atlas of postmenopausal osteoporosis. Second Edition. London: Science Press, 2005:1-24.
3. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8.
4. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8.
5. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2006;21:1453-60.
6. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61.
7. Van Staa TP, Geusens P, Leufkens HGM, Cooper C. Persistence to bisphosphonate treatment in actual clinical practice. European Calcified Tissue Society Meeting, June 25-29, 2005, Geneva, Switzerland [Abstract P610-Su].
8. Ringe JD, Christodoulakos GE, Mellström D, Petto H, et al. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin 2007; 11:2677-87.
9. Ringe JD (Hrsg.). Calcium plus Vitamin D - Schlüsselrolle in der Osteoporosebehandlung. Stuttgart: Georg Thieme Verlag, 2003.
10. Napoli N, Thompson J, Civitelli R, Armamento-Villareal RC. Effects of dietary calcium compared with calcium supplements on estrogen metabolism and bone mineral density. Am J Clin Nutr 2007;85:1428-33.
11. Kipshoven C, Farahmand P, Ringe JD. Zur Epidemiologie der Vitamin- D-Versorgung in Deutschland: Querschnittsuntersuchung an 1 343 nicht selektierten Probanden (DeVID-Studie). Osteologie 2008;l:A55.
12. Bischoff-Ferrari HA, Willet WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293:2257-64.
13. Roux C, Bischoff-Ferrari HA, Papapoulos SE, de Papp AE, et al. New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion. Curr Med Res Opin 2008;24:1363-70.
14. Dachverband der deutschsprachigen wissenschaftlichen Gesellschaften für Osteologie (DVO) e. V. Osteoporose Leitlinie. Langfassung. Stuttgart, New York: Schattauer, 2006.
15. SchnitzerT, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000;12:l-12.
16. Rizzoli R, Greenspan SL, Bone GI, et al. Two-year results of onceweekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17:1988-96.
17. Liberman UA, Weiss SR, Bröil J. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
18. Black DM, Thomson DE, Bauer DC, Ensrud K, et al. Fracture risk reduction with alendronate in women with osteoporosis: The fracture intervention trial. J Clin Endocrinol Metab 2000;85:4118-24.
19. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
20. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5.
21. Saag KG, Emkey R, Schnitzer TJ, Brown JP. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339:292-9.
22. Adachi JD, Saag KG, Delmas PD, Liberman UA. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
23. Black DM, Schwartz AV, Ensrud KE, Cauley JA, et al. Effects of continuing or stopping alendronat after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 2006;296:2927-38.
24. Papaioannou A, loannidis G, Grima D, Adachi JD. Quantification and description of gastrointestinal adverse events (GI AES) in patients switched from branded Fosamax® to generic alendronate. http://www. iscd.org/Visitors/pdfs/ISCD-abstracts.pdf [Abstract #152].
25. Ringe JD. Differences in efficacy and safety of generic and branded once weekly bisphosphonates in postmenopausal women with osteoporosis. Osteoporos Int 2008;19(Suppl):S24.
26. Fachinformation FOSAVANCE und FOSAVANCE 70 mg/5 600 I. E. Tabletten
27. Adami S, Giannini S, Bianchi G, Sinigaglia L, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2008:Epub ahead of print.
28. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk fracture. Osteoporos Int 2007;!8:271-7.